Transfusion-dependent beta thalassemia in Afghanistan: current evidence amid COVID-19 and future recommendations

Shohra Qaderi,Sayed Hamid Mousavi,Attaullah Ahmadi,Shamim Arif,Shekiba Madadi,Sohrab Ayoubi,Don Eliseo Lucero-Prisno
DOI: https://doi.org/10.1080/16078454.2021.1938814
IF: 2.264
2021-01-01
Hematology
Abstract:Transfusion-dependent beta thalassemia (TDT) is a severe form of beta thalassemia in which there is a minimal to no beta globin chain production in the body [1]. This situation eventually leads to major profound and lifelong transfusion-dependent anemia with a high mortality rate of about 85 percent if left untreated [2,3]. TDT patients in older age groups often suffer from functional hyposplenism or asplenia. This increases the risk of bacterial infections leading to serious illness or life-threatening sepsis [2]. Without blood transfusions, thalassemia patients usually die before reaching adolescence. Blood transfusions can help patients have a healthy life and reach adulthood with a near-normal life expectancy. Proper management of thalassemia substantially impacts on the patient's quality of life [1].
hematology
What problem does this paper attempt to address?